Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.

Circulation. Cardiovascular genetics - 1 Aug 2017

van Velzen Hannah G, Schinkel Arend F L, Oldenburg Rogier A, van Slegtenhorst Marjon A, Frohn-Mulder Ingrid M E, van der Velden Jolanda, Michels Michelle

Abstract excerpt

BACKGROUND: MYBPC3 (Myosin-binding protein C) founder mutations account for 35% of hypertrophic cardiomyopathy (HCM) cases in the Netherlands. We compared clinical characteristics and outcome of MYBPC3 founder mutation (FG+) HCM with nonfounder genotype-positive (G+) and genotype-negative (G-) HCM. METHODS AND RESULTS: The study included 680 subjects: 271 FG+ carriers, 132 G+ probands with HCM, and 277 G-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy, Hypertrophic
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Echocardiography

Share to Follow-Up Studies

Share to Founder Effect

Share to Kaplan-Meier Estimate

Share to Magnetic Resonance Imaging, Cine

Share to Sex Factors

Source

Identifiers

PMID: 28794111
DOI: 10.1161/CIRCGENETICS.116.001660

Genes

MYBPC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.PMID 28794111Read ↗

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers.Semantic proximity Read ↗

The Long-Term Clinical Progression of Genotype-Positive/Phenotype-Negative Patients With Hypertrophic Cardiomyopathy.Semantic proximity Read ↗

Genetic determinants of the phenotype in a Swedish cohort of patients with hypertrophic cardiomyopathySemantic proximity Read ↗

A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.Semantic proximity Read ↗

Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene.Semantic proximity Read ↗

Genotype-phenotype associations in sarcomeric hypertrophic cardiomyopathy associated with mutations in the MYBPC3 gene: Systematic review and meta-analysis.Semantic proximity Read ↗

Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic CardiomyopathySemantic proximity Read ↗

Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.Semantic proximity Read ↗

Clinical Outcome of Hypertrophic Cardiomyopathy in Probands with the Founder Variant c.913_914del in MYBPC3: A Slovenian Cohort Study.Semantic proximity Read ↗

Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3.Semantic proximity Read ↗

Family screening for hypertrophic cardiomyopathy: initial cardiologic assessment, and long-term follow-up of genotype-positive phenotype-negative individualsSemantic proximity Read ↗

The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.